Information Provided By:
Fly News Breaks for June 28, 2016
NURO
Jun 28, 2016 | 07:05 EDT
Rodman & Renshaw analyst Raghuram Selvaraju started NeuroMetrix with a Buy rating and $4.50 price target. The company's Quell platform is differentiated from competitors in that it is a drug-free, non-invasive and wearable neuro-stimulation device that can provide systemic and effective pain relief, Selvaraju tells investors in a research note.
News For NURO From the Last 2 Days
There are no results for your query NURO